Company Listing
Solexa

Solexa developed the next-generation sequencing (NGS) technology that has become the most widely adopted in the industry, and has helped to transform life science and clinical research. The company was founded with funding from Abingworth and completed a reverse takeover of Lynx Therapeutics in March 2005. Subsequently, it was acquired by Illumina for $600 million in January 2007.

BACK
Location
Cambridge, England

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Solexa developed the next-generation sequencing (NGS) technology that has become the most widely adopted in the industry, and has helped to transform life science and clinical research. The company was founded with funding from Abingworth and completed a reverse takeover of Lynx Therapeutics in March 2005. Subsequently, it was acquired by Illumina for $600 million in January 2007.

Location
Cambridge, England
BACK
 
Copyright Abingworth 2017